Dina Chaya is a Partner with NeoMed Management and Advisor to Omega Funds. Dina has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001. Previously at 3i plc in London and Index Ventures in Geneva, her successful investments include Endosense, EUSA Pharma, Novexel and Wilson Therapeutics. She was also a member of the Venture Capital Platform Council of Invest Europe.
Dr. Chaya currently serves on the board of directors of Anjarium Biosciences, Imago BioSciences, Oxular and Spruce Biosciences. Dina is a CFA charterholder and holds a Ph.D. degree in molecular and cellular biology from Paris VI University, France and carried out postdoctoral research at Brown University and at the Fox Chase Cancer Centre in Philadelphia.